Last reviewed · How we verify

Spinal Anesthesia with Bupivacaine

University Hospital of North Norway · FDA-approved active Small molecule Quality 5/100

Spinal Anesthesia with Bupivacaine, marketed by the University Hospital of North Norway, holds a position in the spinal anesthesia segment. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports market stability. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic nameSpinal Anesthesia with Bupivacaine
Also known asSpinal Block
SponsorUniversity Hospital of North Norway
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: